Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Rhea-AI Summary

Talphera will release its third quarter 2024 financial results on November 13, 2024 after market close. The company will also host a live webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The webcast can be accessed through the Investors section of Talphera's website and will include a slide presentation. A replay will be available for 90 days post-event. Investors can join the conference call by dialing 1-800-836-8184 (North America) or 1-646-357-8785 (international) using the conference ID 89949.

SAN MATEO, Calif., Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business.

Webcast Information

The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.

Conference Call Information

Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 89949.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA). Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.

This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-third-quarter-2024-financial-results-and-corporate-update-call-and-webcast-on-wednesday-november-13-2024-302297952.html

SOURCE Talphera, Inc.

FAQ

When will Talphera release its Q3 2024 financial results?

Talphera will release its Q3 2024 financial results on November 13, 2024, after market close.

What time is Talphera's Q3 2024 financial results webcast?

The webcast is scheduled for 4:30 p.m. Eastern Time on November 13, 2024.

How can I access the Talphera Q3 2024 financial results webcast?

You can access the webcast through the Investors section of Talphera's website.

What is the conference call ID for Talphera's Q3 2024 financial results?

The conference call ID is 89949.

Will there be a replay available for Talphera's Q3 2024 financial results webcast?

Yes, a replay will be available on Talphera's website for 90 days following the event.